Fezolinetant
chemical compound
Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, selective neurokinin-3 (NK3) receptor antagonist taken by mouth. It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.
The most common side effects of fezolinetant include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.
Fezolinetant was approved for medical use in the United States in May 2023, and it was approved in the European Union in December 2023. Fezolinetant is the first NK3 receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause. The FDA considers it to be a first-in-class medication.
Medical uses
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Adverse effects
In September 2024, the US FDA added a warning to the prescribing label that fezolinetant can cause rare but serious liver injury.
History
In May 2017, fezolinetant had completed phase I and phase IIa clinical trials for hot flashes in postmenopausal females.
“Fezolinetant” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Fezolinetant, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Fezolinetant” is worth following because a concise public description often conceals a longer documentary argument. Here, Fezolinetant, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated May 2, 2026. The linked authority identifier is Q27269455. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2017, 2023 and 2024.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Fezolinetant”, its source revision and the description used here.
- Expand the search: follow Fezolinetant primary sources, Fezolinetant archive and Fezolinetant research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Fezolinetant”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Fezolinetant” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.